{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:06:26Z","timestamp":1789059986106,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejca.2026.116982","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T15:11:53Z","timestamp":1786201913000},"page":"116982","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Evaluating safety: Number needed to harm analyses of androgen receptor inhibitors in advanced prostate cancer"],"prefix":"10.1016","volume":"246","author":[{"given":"Daniel J.","family":"George","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6068-9474","authenticated-orcid":false,"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia K.","family":"Morgans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah D.","family":"McManus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen Yen","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Duflot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Upton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.ejca.2026.116982_bib1","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ejca.2026.116982_bib2","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ejca.2026.116982_bib3","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","article-title":"Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer","volume":"382","author":"Sternberg","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2026.116982_bib4","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","article-title":"ESMO Guidelines Committee. Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents","volume":"34","author":"Fizazi","year":"2023","journal-title":"Ann Oncol"},{"issue":"32","key":"10.1016\/j.ejca.2026.116982_bib5","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116982_bib6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ejca.2026.116982_bib7","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N Engl J Med"},{"issue":"36","key":"10.1016\/j.ejca.2026.116982_bib8","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","volume":"42","author":"Saad","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116982_bib9","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.annonc.2025.12.009","article-title":"Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"37","author":"Walz","year":"2026","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116982_bib10","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/JU.0000000000001767","article-title":"Indirect comparison of darolutamide versus apalutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer","volume":"206","author":"Halabi","year":"2021","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116982_bib11","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.euf.2024.11.004","article-title":"Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer patients: an updated network meta-analysis including ARANOTE data","volume":"11","author":"Hoeh","year":"2025","journal-title":"Eur Urol Focus"},{"issue":"2","key":"10.1016\/j.ejca.2026.116982_bib12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3390\/cancers17020205","article-title":"An updated systematic review and network meta-analysis of first-line triplet vs. doublet therapies for metastatic hormone-sensitive prostate cancer","volume":"17","author":"Matsukawa","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.ejca.2026.116982_bib13","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1007\/s10147-020-01777-9","article-title":"Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis","volume":"25","author":"Mori","year":"2020","journal-title":"Int J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2026.116982_bib14","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1080\/14796694.2025.2526324","article-title":"Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC","volume":"21","author":"Armstrong","year":"2025","journal-title":"Future Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116982_bib15","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s10865-022-00288-4","article-title":"Symptom burden profiles in men with advanced prostate cancer undergoing androgen deprivation therapy","volume":"45","author":"Noriega Esquives","year":"2022","journal-title":"J Behav Med"},{"issue":"7","key":"10.1016\/j.ejca.2026.116982_bib16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/oncolo\/oyae019","article-title":"Extended safety and tolerability of darolutamide for nonmetastatic castration-resistant prostate cancer and adverse event time course in ARAMIS","volume":"29","author":"Shore","year":"2024","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.ejca.2026.116982_bib17","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1200\/CCI.19.00103","article-title":"Patient-centered approach to benefit-risk characterization using number needed to benefit and number needed to harm: advanced non-small-cell lung cancer","author":"Raju","year":"2020","journal-title":"JCO Clin Cancer Inform"},{"issue":"3","key":"10.1016\/j.ejca.2026.116982_bib18","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.4088\/JCP.15f09870","article-title":"The numbers needed to treat and harm (NNT, NNH) statistics: what they tell us and what they do not","volume":"76","author":"Andrade","year":"2015","journal-title":"J Clin Psychiatry"},{"issue":"14","key":"10.1016\/j.ejca.2026.116982_bib19","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.2217\/fon-2020-1291","article-title":"Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial","volume":"17","author":"Fizazi","year":"2021","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116982_bib20","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.eururo.2020.08.011","article-title":"Apalutamide and overall survival in prostate cancer","volume":"79","author":"Smith","year":"2021","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116982_bib21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ejca.2026.116982_bib22","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116982_bib23","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2022-1-2","article-title":"Benefit-risk assessment of sonidegib and vismodegib in the treatment of locally advanced basal cell carcinoma","volume":"11","author":"Garc\u00eda Ruiz","year":"2022","journal-title":"Drugs Context"},{"issue":"3","key":"10.1016\/j.ejca.2026.116982_bib24","first-page":"E146","article-title":"Time trends of drug-specific actionable adverse events among patients on androgen receptor antagonists: implications for remote monitoring","volume":"16","author":"Fleshner","year":"2022","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.ejca.2026.116982_bib25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ctrv.2017.03.001","article-title":"The role of drug-drug interactions in prostate cancer treatment: focus on abiraterone acetate\/prednisone and enzalutamide","volume":"55","author":"Del Re","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.ejca.2026.116982_bib26","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11523-019-00674-0","article-title":"Evaluation of clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial","volume":"14","author":"Shore","year":"2019","journal-title":"Target Oncol"},{"key":"10.1016\/j.ejca.2026.116982_bib27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.euros.2021.10.003","article-title":"A systematic review of patients\u2019 values, preferences, and expectations for the treatment of metastatic prostate cancer","volume":"36","author":"Connor","year":"2022","journal-title":"Eur Urol Open Sci"},{"issue":"6","key":"10.1016\/j.ejca.2026.116982_bib28","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40271-023-00638-7","article-title":"Discrete-choice experiment to understand the preferences of patients with hormone-sensitive prostate cancer in the USA, Canada, and the UK","volume":"16","author":"Gonzalez","year":"2023","journal-title":"Patient"},{"issue":"1","key":"10.1016\/j.ejca.2026.116982_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102254","article-title":"Patient preferences for metastatic prostate cancer treatment: a discrete choice experiment","volume":"23","author":"Hong","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ejca.2026.116982_bib30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.euros.2023.03.001","article-title":"Patient and general population preferences regarding the benefits and harms of treatment for metastatic prostate cancer: a discrete choice experiment","volume":"51","author":"Menges","year":"2023","journal-title":"Eur Urol Open Sci"},{"issue":"6","key":"10.1016\/j.ejca.2026.116982_bib31","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.euo.2024.04.001","article-title":"Patient preference of apalutamide versus enzalutamide for recurrent or metastatic hormone-sensitive prostate cancer: an open-label, randomized, crossover trial","volume":"7","author":"Ng","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116982_bib32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12894-020-00631-4","article-title":"Physician preferences for non-metastatic castration-resistant prostate cancer treatment","volume":"20","author":"Srinivas","year":"2020","journal-title":"BMC Urol"},{"issue":"18","key":"10.1016\/j.ejca.2026.116982_bib33","doi-asserted-by":"crossref","first-page":"6586","DOI":"10.1002\/cam4.3321","article-title":"Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer treatment","volume":"9","author":"Srinivas","year":"2020","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.ejca.2026.116982_bib34","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.eururo.2023.05.009","article-title":"A randomized, open-label, cross-over phase 2 trial of darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer: patient preference and cognitive function in ODENZA","volume":"85","author":"Colomba","year":"2024","journal-title":"Eur Urol"},{"issue":"Suppl 16","key":"10.1016\/j.ejca.2026.116982_bib35","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1200\/JCO.2026.44.16_suppl.5005","article-title":"Cognitive effects of darolutamide vs enzalutamide: Results of ARACOG (AFT-47), a randomized clinical trial from the Alliance for Clinical Trials in Oncology","volume":"44","author":"Morgans","year":"2026","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116982_bib36","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of patients with advanced prostate cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116982_bib37","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/cts.13451","article-title":"Risk of cognitive impairment in men with advanced prostate cancer treated with NHAs: a systematic review and network meta-analysis","volume":"16","author":"Huang","year":"2023","journal-title":"Clin Transl Sci"},{"issue":"3","key":"10.1016\/j.ejca.2026.116982_bib38","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11523-023-00959-5","article-title":"Comparison of cerebral blood flow in regions relevant to cognition after enzalutamide, darolutamide, and placebo in healthy volunteers: a randomized crossover trial","volume":"18","author":"Williams","year":"2023","journal-title":"Target Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492600763X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492600763X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:09:30Z","timestamp":1789056570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492600763X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":38,"alternative-id":["S095980492600763X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116982","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating safety: Number needed to harm analyses of androgen receptor inhibitors in advanced prostate cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116982","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116982"}}